1163.6000 5.20 (0.45%)
NSE Apr 17, 2025 15:31 PM
Volume: 2.8M
 

Emkay
Adjusted for the milestone payment received from Journey Medical Corp, 3QFY25 EBITDA for Dr Reddy’s was below street/our estimates. The PAT miss was higher on account of lower other income.
Dr. Reddy's Laborato.. has an average target of 1347.12 from 10 brokers.
More from Dr. Reddy's Laboratories Ltd.
Recommended